Coeptis Therapeutics Holdings, Inc.
COEP
$15.92
-$0.04-0.25%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 18.29% | 219.08% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 18.29% | 219.08% | |||
| Cost of Revenue | 0.00% | 0.00% | |||
| Gross Profit | 23.67% | 778.53% | |||
| SG&A Expenses | -55.71% | 10.66% | |||
| Depreciation & Amortization | 0.00% | 0.00% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -42.51% | 14.61% | |||
| Operating Income | 45.21% | -11.44% | |||
| Income Before Tax | 33.12% | -26.71% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 33.12% | -26.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 176.86% | -157.10% | |||
| Net Income | 39.69% | -48.54% | |||
| EBIT | 45.21% | -11.44% | |||
| EBITDA | 48.37% | -12.34% | |||
| EPS Basic | 52.65% | -22.54% | |||
| Normalized Basic EPS | 67.79% | -46.90% | |||
| EPS Diluted | 52.65% | -22.54% | |||
| Normalized Diluted EPS | 67.79% | -46.90% | |||
| Average Basic Shares Outstanding | 27.38% | 21.22% | |||
| Average Diluted Shares Outstanding | 27.38% | 21.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||